RegenMed Development Organization
ReMDO is a U.S.-based 501(c)(3) non-profit that coordinates an ecosystem to accelerate translation and commercialization of regenerative medicine technologies. It operates an integrated program providing a shared biomanufacturing test bed, an innovation accelerator, workforce development, regulatory guidance, multi‑partner consortia, and a portfolio of research programs (bioinks, standardized media, scalable bioreactors, and automated cell isolation) to de-risk technologies and support scale-up and clinical translation.
Industries
Nr. of Employees
small (1-50)
RegenMed Development Organization
Winston-Salem, NC (Innovation Quarter) — see source
Products
RegeneratOR Test Bed
Supports regenerative medicine start-ups with access to biomanufacturing equipment and resources for prototyping and product development.
Universal Bioink Program
Develops hydrogels as a universal bioink for various 3D bioprinting platforms, compatible with different cell types.
RegeneratOR Innovation Accelerator
Facilitates innovation from research to commercialization for regenerative medicine start-ups with space and business support.
Standardized Cell Culture Media
Creates a xeno-free basal medium for human cell growth, simplifying regulatory review and reducing costs.
Bioreactor Program
Develops a standardized bioreactor platform for maturing regenerative medicine products, ensuring scalability and regulatory compliance.
Cell Isolation Program
Automates cell isolation and purification to produce defined cell populations for clinical manufacturing.
RegeneratOR Test Bed
Supports regenerative medicine start-ups with access to biomanufacturing equipment and resources for prototyping and product development.
Universal Bioink Program
Develops hydrogels as a universal bioink for various 3D bioprinting platforms, compatible with different cell types.
RegeneratOR Innovation Accelerator
Facilitates innovation from research to commercialization for regenerative medicine start-ups with space and business support.
Standardized Cell Culture Media
Creates a xeno-free basal medium for human cell growth, simplifying regulatory review and reducing costs.
Bioreactor Program
Develops a standardized bioreactor platform for maturing regenerative medicine products, ensuring scalability and regulatory compliance.
Cell Isolation Program
Automates cell isolation and purification to produce defined cell populations for clinical manufacturing.
Services
On-site access to modular biomanufacturing equipment, controlled culture environments, technical support for prototyping and process optimization, and integration with smart manufacturing analytics.
Workspace and programmatic support housed with research partners, offering market validation, business strategy, and access to equipment and collaborators for commercialization activities.
Coordinated research initiatives focused on bioink development, standardized xeno-free cell culture media, scalable bioreactor systems, and automated cell isolation to de-risk technologies for commercialization.
Regulatory advisory services offering pre-submission strategies and guidance for regulatory interactions and submission planning, including assay and quality strategy input.
Programs connecting developers with clinical trial infrastructure, patient populations, and clinical research partners to accelerate trial start-up and enrollment.
Convene industry, academia, and government stakeholders to identify manufacturing challenges, develop roadmaps, and catalyze standards and workforce initiatives.
On-site access to modular biomanufacturing equipment, controlled culture environments, technical support for prototyping and process optimization, and integration with smart manufacturing analytics.
Workspace and programmatic support housed with research partners, offering market validation, business strategy, and access to equipment and collaborators for commercialization activities.
Coordinated research initiatives focused on bioink development, standardized xeno-free cell culture media, scalable bioreactor systems, and automated cell isolation to de-risk technologies for commercialization.
Regulatory advisory services offering pre-submission strategies and guidance for regulatory interactions and submission planning, including assay and quality strategy input.
Programs connecting developers with clinical trial infrastructure, patient populations, and clinical research partners to accelerate trial start-up and enrollment.
Convene industry, academia, and government stakeholders to identify manufacturing challenges, develop roadmaps, and catalyze standards and workforce initiatives.
Expertise Areas
- Biomanufacturing scale-up and automation
- Smart manufacturing and process analytics
- Regulatory strategy and FDA engagement for regenerative products
- Clinical trial facilitation and patient network access
Key Technologies
- Closed-system modular cell and tissue manufacturing
- Scalable automated bioreactors
- IoT-enabled manufacturing monitoring
- Machine learning for process control and analytics
News & Updates
Two-day industry meeting focused on standards, next-generation manufacturing, AI/ML, logistics, and workforce development in regenerative medicine.
Industry convening on precision medicine, standards, biomanufacturing, shipping/logistics, and workforce development.
Announcement of a regulatory advisory initiative to guide regenerative medicine developers through FDA engagement and regulatory strategy.
Launch of a shared test bed providing modular biomanufacturing infrastructure and resources for start-ups and companies.
Grant awards supporting collaborative technology development in biomanufacturing, standards, quality control, and AI/automation.
Educational webinar series addressing clinical development and guidance for iPSC-based regenerative medicine approaches.
Two-day industry meeting focused on standards, next-generation manufacturing, AI/ML, logistics, and workforce development in regenerative medicine.
Industry convening on precision medicine, standards, biomanufacturing, shipping/logistics, and workforce development.
Announcement of a regulatory advisory initiative to guide regenerative medicine developers through FDA engagement and regulatory strategy.
Launch of a shared test bed providing modular biomanufacturing infrastructure and resources for start-ups and companies.
Grant awards supporting collaborative technology development in biomanufacturing, standards, quality control, and AI/automation.
Educational webinar series addressing clinical development and guidance for iPSC-based regenerative medicine approaches.